Q2 2024 Earnings Estimate for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Issued By Wedbush

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Stock analysts at Wedbush lifted their Q2 2024 EPS estimates for shares of Kiniksa Pharmaceuticals in a report issued on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.06) per share for the quarter, up from their prior estimate of ($0.16). Wedbush currently has a “Outperform” rating and a $30.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is $0.06 per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.02 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2027 earnings at $1.26 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The business had revenue of $79.90 million during the quarter, compared to analysts’ expectations of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 65.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.18) EPS.

A number of other equities analysts have also recently commented on the stock. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Evercore ISI lifted their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday.

Kiniksa Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:KNSA opened at $17.88 on Thursday. The stock has a market cap of $1.26 billion, a PE ratio of 162.55 and a beta of 0.27. The company’s fifty day moving average is $19.27 and its 200 day moving average is $18.00. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $22.09.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Peregrine Capital Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the first quarter valued at about $4,657,000. Allspring Global Investments Holdings LLC increased its position in shares of Kiniksa Pharmaceuticals by 18.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 61,106 shares of the company’s stock valued at $1,206,000 after buying an additional 9,490 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in shares of Kiniksa Pharmaceuticals by 29.2% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 124,878 shares of the company’s stock valued at $2,464,000 after buying an additional 28,237 shares during the period. Opaleye Management Inc. purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at about $640,000. Finally, Parkman Healthcare Partners LLC increased its position in shares of Kiniksa Pharmaceuticals by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 615,693 shares of the company’s stock valued at $10,799,000 after buying an additional 105,883 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 5,582 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total value of $117,222.00. Following the transaction, the chief executive officer now owns 65,012 shares in the company, valued at $1,365,252. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sanj K. Patel sold 5,582 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the transaction, the chief executive officer now owns 65,012 shares in the company, valued at approximately $1,365,252. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock worth $709,929 in the last 90 days. 54.23% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.